Adaptive Biotechnologies Corp

For the period ended Jun 30, 2024. Filed Aug 1, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 1, 2024

ADPT$30.26+8.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Revenue	$43,190	$48,926	$85,063	$86,573
Operating expenses
Cost of revenue	19,317	17,910	37,368	36,591
Research and development	25,353	32,237	55,598	64,838
Sales and marketing	20,314	23,872	42,633	46,180
General and administrative	17,895	22,302	37,492	43,133
Amortization of intangible assets	424	423	847	842
Impairment of long-lived assets	7,205	—	7,205	—
Total operating expenses	90,508	96,744	181,143	191,584
Loss from operations	(47,318)	(47,818)	(96,080)	(105,011)
Interest and other income, net	3,766	3,612	7,988	6,636
Interest expense	(2,696)	(3,605)	(5,689)	(7,136)
Net loss	(46,248)	(47,811)	(93,781)	(105,511)
Add: Net loss attributable to noncontrolling interest	26	1	52	2
Net loss attributable to Adaptive Biotechnologies Corporation	$(46,222)	$(47,810)	$(93,729)	$(105,509)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$(0.31)	$(0.33)	$(0.64)	$(0.73)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	147,414,095	144,397,693	146,600,811	143,956,867

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.